Wasatch Microfluidics, a Salt Lake City, UT-based company dedicated to the advancement of label-free biomolecular interaction analysis, closed a $2m funding round.
Backers included existing investors and Kirk Ririe, founder of BioFire Diagnostics.
The funding will be used to expand sales and marketing activity.
Led by Josh Eckman, CEO, Wasatch Microfluidics provides label free analysis platforms for biomolecular interaction analysis. Its product package, which groups early stage antibodies, is already being sold to major pharmaceutical companies.
In partnership with IBIS Technologies, the company has made the MX96 SPR imager available in the United States, Australia and Asia. The combination of its CFM Printer and the MX96 enables high sensitivity label free analysis of up to 10,000 interactions in an automated format.
Wasatch has also received six Phase I SBIR awards and two Phase II awards through the National Institutes of Health and the National Science Foundation.